BLAINTRAVENOUSVIAL
Approved
Jul 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
5/8 — Partial
ELITEK (rasburicase) by Sanofi is humans, uric acid is the final step in the catabolic pathway of purines. First approved in 2002.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELITEK (rasburicase) is an intravenous recombinant uricase enzyme approved in 2002 for management of uric acid levels in cancer patients at risk of tumor lysis syndrome. It catalyzes enzymatic oxidation of poorly soluble uric acid into allantoin, a more soluble and inactive metabolite. The drug is administered as an IV infusion and represents a specialized oncology supportive care therapy.
$0.571MPart D
LOE ApproachingDeclining
Product is nearing loss of exclusivity with minimal Part D volume, indicating a contracting team and shift toward generic/biosimilar defense rather than growth initiatives.
Mechanism of Action
humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzes enzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite (allantoin).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
MIELITEKO Lifestyle Intervention Study
Started Aug 2022
Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
Started May 2020
50 enrolled
Lymphoma
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Started Apr 2011
55 enrolled
LeukemiaLymphoma
Elitek (Rasburicase) Immuno-Monitoring Study
Started Feb 2010
1 enrolled
Tumor Lysis Syndrome
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
Started Jan 2008
82 enrolled
Tumor Lysis Syndrome
Worked on ELITEK at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.